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Genome	sequencing	has	become	a	powerful	tool	for	studying	emerging	infectious	diseases;	however,	
genome	sequencing	directly	from	clinical	samples	(i.e.	without	isolation)	remains	challenging	for	
viruses	such	as	Zika,	where	metagenomic	sequencing	methods	may	generate	insufficient	numbers	of	
viral	reads.	Here	we	present	a	protocol	for	generating	coding-sequence	complete	genomes	comprising	
an	online	primer	design	tool,	a	novel	multiplex	PCR	enrichment	protocol,	optimised	library	
preparation	methods	for	the	portable	MinION	sequencer	(Oxford	Nanopore	Technologies)	and	the	
Illumina	range	of	instruments,	and	a	bioinformatics	pipeline	for	generating	consensus	sequences.	The	
MinION	protocol	does	not	require	an	internet	connection	for	analysis,	making	it	suitable	for	field	
applications	with	limited	connectivity.	Our	method	relies	on	multiplex	PCR	for	targeted	enrichment	of	
viral	genomes	from	samples	containing	as	few	as	50	genome	copies	per	reaction.	Viral	consensus	
sequences	can	be	achieved	starting	with	clinical	samples	in	1-2	days	following	a	simple	laboratory	
workflow.	This	method	has	been	successfully	used	by	several	groups	studying	Zika	virus	evolution	and	
is	facilitating	an	understanding	of	the	spread	of	the	virus	in	the	Americas.	
	
  
 	
INTRODUCTION	
Genome	sequencing	of	viruses	has	been	used	to	study	the	spread	of	disease	in	outbreaks	1.	Real-time	
genomic	surveillance	is	important	in	managing	viral	outbreaks,	as	it	can	provide	insights	into	how	viruses	
transmit,	spread,	and	evolve	1–4.	Such	work	depends	on	rapid	sequencing	of	viral	material	directly	from	
clinical	samples,	i.e.	without	the	need	to	isolate	the	virus	in	pure	culture.	During	the	Ebola	virus	
epidemic	of	2013-2016,	prospective	viral	genome	sequencing	was	able	to	provide	critical	information	on	
virus	evolution	and	help	inform	epidemiological	investigations	3–6.	Sequencing	directly	from	clinical	
samples	(without	culture	isolation)	is	faster,	less	laborious,	and	more	amenable	to	near-patient	work	
than	time	consuming	culture-based	methods.	Metagenomics,	the	process	of	sequencing	the	total	
nucleic	acid	content	in	a	sample	(typically	cDNA	or	DNA),	has	been	successfully	applied	to	both	virus	
discovery	and	diagnostics	7–9.	Metagenomic	approaches	have	seen	rapid	adoption	over	the	past	decade,	
fuelled	by	relentless	improvements	in	the	yield	of	high-throughput	sequencing	instruments	5,10–12.	
Whole-genome	sequencing	of	Ebola	virus	directly	from	clinical	samples	without	amplification	was	
possible	due	to	the	extremely	high	virus	copy	numbers	found	in	acute	cases	13–15.	However,	direct	
metagenomic	sequencing	from	clinical	samples	poses	challenges	with	regards	to	sensitivity:	genome	
coverage	may	be	low	or	absent	when	attempting	to	sequence	viruses	that	are	present	at	low	abundance	
in	a	sample	with	high	levels	of	host	nucleic	acid	background.	During	recent	work	on	the	Zika	virus	
epidemic	16,	we	found	that	it	was	difficult	to	generate	whole-genome	sequences	directly	from	clinical	
samples	using	metagenomic	approaches	(Table	1).	These	samples	had	Ct	values	between	33.9	and	35.9	
(equivalent	to	10-48	genome	copies	per	microlitre).		Before	sequencing,	these	samples	were	depleted	of	
human	rRNA	and	prepared	for	metagenomic	sequencing	on	the	Illumina	MiSeq	platform	as	previously	
described	2,17.		In	these	cases,	sequences	from	Zika	virus	comprised	<0.01%	of	the	dataset,	resulting	in	
incomplete	coverage.	Greater	coverage	and	depth	is	critical	for	accurate	genome	reconstruction	and	
subsequent	phylogenetic	inference.	Additionally,	there	are	significant	sequencing	and	storage	costs	
associated	with	generating	large	sequencing	datasets,	and	these	approaches	currently	do	not	lend	
themselves	to	lower-throughput	portable	sequencing	devices	such	as	the	Oxford	Nanopore	MinION.	
	
Target	enrichment	is	often	required	to	generate	complete	viral	genome	coverage	from	clinical	samples	
in	an	economic	way	18.	Enrichment	can	be	achieved	directly	through	i)	isolation	in	culture,	ii)	
oligonucleotide	bait	probes	targeting	the	virus	of	interest,	or	iii)	indirectly	via	host	nucleic	acid	
depletion.	Amplification	may	also	be	required	to	generate	sufficient	material	for	sequencing	(>5	ng	for	
typical	Illumina	protocols,	and	100-1000	ng	for	MinION).	Polymerase	chain	reaction	(PCR)	can	provide	
both	target	enrichment	and	amplification	in	a	single	step,	and	is	relatively	cheap,	available,	and	fast	
compared	to	other	methods.	In	order	to	generate	coding-sequence	complete	coverage,	a	tiling	amplicon	
scheme	is	commonly	employed	19–21.	During	our	work	with	Ebola	virus	we	were	able	to	reliably	amplify	
>95%	of	the	genome	by	sequencing	eleven	long	amplicons	(1-2.5	kb	in	length)	on	the	MinION	5.	The	
likelihood	of	long	fragments	being	present	in	the	sample	reduces	with	lower	virus	abundance.	
Therefore,	we	anticipated	that	for	viruses	like	Zika	that	are	present	at	low	abundance	in	clinical	samples,	
we	would	be	more	likely	to	amplify	shorter	fragments.	As	an	extreme	example	of	this	approach,	a	recent	
approach	termed	‘jackhammering’	was	used	to	amplify	degraded	HIV-1	samples	stored	for	over	40	years	
and	used	200-300	nucleotide	(nt)	amplicons	to	help	maximise	sequence	recovery	22.	
 	
Using	shorter	amplicons	necessitates	a	larger	number	of	products	to	generate	a	tiling	path	across	a	
target	genome.	To	do	this	in	individual	reactions	would	require	a	large	number	of	manual	pipetting	
steps	and	therefore	the	potential	for	mistakes	and	a	heightened	risk	of	cross-contamination,	as	well	as	a	
greater	cost	in	time	and	consumables.	To	solve	these	problems,	we	designed	a	multiplex	assay	to	carry	
out	tens	of	reactions	in	an	individual	tube.	This	method	has	been	subsequently	used	to	perform	Zika	
sequencing	in	order	to	understand	the	spread	of	Zika	virus	in	the	Americas	16,23–26.	Our	resulting	step-by-
step	protocol	allows	any	researcher	to	successfully	amplify	and	sequence	low	abundance	viruses	directly	
from	clinical	samples.	The	method	has	other	potential	uses	that	are	not	demonstrated	here.	One	
potential	application	is	to	generate	a	panel	for	multi-locus	sequencing	typing	genes	in	bacteria,	fungi	
and	yeasts.	Simultaneously,	antibiotic-resistance-determining	genes	or	key	virulence	genes	could	also	be	
targeted	in	the	same	assay.	The	scheme	could	also	be	used	to	sequence	chloroplast	and	mitochondrial	
genomes.	
	
Choice	of	amplicon	length	
The	choice	of	amplicon	length	when	designing	primer	pools	for	sequencing	is	important.	There	is	an	
inverse	relationship	between	amplicon	length	and	number	of	primer	pairs.	It	is	believed	that	increasing	
numbers	of	primer	pairs	reduces	the	likelihood	of	successful	amplification	of	each	region	due	to	
interaction	between	primers	18.	Longer	amplicons	are	preferred	as	they	mean	fewer	primer	pairs	are	
needed	per	reaction.	They	also	increase	the	amount	of	linkage	information	that	can	be	recovered	into	
haplotypes,	of	importance	for	investigation	of	within-host	diversity.	On	the	Illumina	platform,	600	bases	
is	the	maximum	size	of	amplicon	that	can	be	obtained	without	an	additional	fragmentation	step	using	
this	protocol	(using	600	cycle	kits	in	paired-end	mode,	i.e.	paired	300	bases	without	any	overlap),	
although	read	accuracy	may	degrade	significantly	during	the	last	50	cycles	.	On	the	Oxford	Nanopore	
MinION,	there	is	no	limit	to	the	maximum	amplicon	length	that	can	be	sequenced;	the	effective	
limitation	will	relate	to	the	performance	of	the	reverse	transcription	and	polymerase	chain	reaction	step	
(practically	around	5	kb).	However,	longer	amplicons	are	less	likely	to	amplify	successfully	when	viral	
copy	number	is	low,	or	there	is	significant	sample	degradation	(e.g.	due	to	inadequate	storage).	
	
Limitations	of	tiling	amplicon	sequencing	
Our	method	is	not	suitable	for	the	discovery	of	new	viruses	or	sequencing	highly	diverse	or	recombinant	
viruses	as	primer	schemes	are	virus	genome-specific.	Amplicon	sequencing	is	prone	to	coverage	
dropouts	that	may	result	in	incomplete	genome	coverage,	especially	at	lower	abundances,	and	the	loss	
of	both	the	5’	and	3’	regions	that	fall	in	regions	not	covered	by	primer	pairs.	Sequencing	of	complete	5’	
and	3’-UTR	regions	may	require	alternative	techniques	such	as	RACE	27.	This	protocol	has	not	been	
validated	for	discovery	of	intra-host	nucleotide	variants,	and	we	expect	that	minor	allele	frequencies	will	
not	be	reliably	recovered	when	amplifying	from	very	small	amounts	of	starting	virus,	as	shown	by	
Metsky	et	al	25.	
	
The	majority	of	primers	are	expected	to	work	even	when	pooled	in	equimolar	amounts,	meaning	largely	
complete	genomes	can	be	recovered	without	optimisation.	The	chikungunya	virus	data	shown	in	Table	2	
was	generated	without	any	optimisation.	However,	to	achieve	coding-sequence	complete	genomes,	
 problem	primers	may	need	to	be	replaced	or	concentration	relative	to	other	primers	adjusted	in	an	
iterative	manner.	Full	coverage	should	be	achievable	for	the	majority	of	samples,	however	coverage	is	
expected	to	correlate	with	viral	abundance	(Table	3).	We	expect	that	this	method	will	work	for	larger	
virus	genomes,	but	we	have	not	tested	this	protocol	with	viral	genomes	longer	than	12	kb.	Targeted	
methods	are	also	highly	sensitive	to	amplicon	contamination	from	previous	experiments.	Extreme	
caution	should	be	taken	to	keep	pre-PCR	areas,	reagents,	and	equipment	free	of	contaminating	
amplicons.	It	is	plausible	that	as	the	number	of	primer	pairs	increases	that	competitive	inhibition	may	
decrease	PCR	efficiency,	although	the	high	annealing	temperature	employed	in	this	protocol	should	
reduce	this	risk.		
	
EXPERIMENTAL	DESIGN	
Description	of	the	protocol	
We	describe	a	fully	integrated	end-to-end	protocol	for	rapid	sequencing	of	viral	genomes	directly	from	
clinical	samples.	The	protocol	proceeds	in	four	steps;	i)	multiplex	primer	pool	design,	ii)	multiplex	PCR	
protocol,	iii)	sequencing	on	MinION	or	Illumina	instruments	and	iv)	bioinformatics	analysis	and	QC	
(Figure	1).	
	
Primer	Design	
We	developed	a	web-based	primer	design	tool	entitled	Primal	Scheme	(https://primal.zibraproject.org),	
which	provides	a	complete	pipeline	for	the	development	of	efficient	multiplex	primer	schemes.	Each	
scheme	is	a	set	of	oligonucleotide	primer	pairs	that	generate	overlapping	products.	Together,	the	
amplicons	generated	by	the	pairs	span	the	target	genome	or	region	of	interest	(Figure	2).		
	
As	input,	Primal	Scheme	requires	a	FASTA	file	containing	one	or	more	reference	genomes.	The	user	
specifies	a	desired	PCR	amplicon	length	(default	400	nt,	suggested	values	between	200	and	2000	nt),	
and	the	desired	length	of	overlap	between	neighbouring	amplicons	(default	75	nt).	Using	a	shorter	
amplicon	length	may	be	useful	for	samples	where	longer	products	fail	to	amplify	(e.g.	when	the	virus	
nucleic	acid	is	highly	degraded).	However,	if	amplicon	lengths	become	too	short	(e.g.	<300	nt),	it	may	
not	be	possible	to	find	suitable	primer	pairs:	reducing	the	overlap	parameter	may	help	with	this.	
	
The	Primal	Scheme	software	performs	the	following	steps:	
● Generate	candidate	primers:	The	first	sequence	listed	in	the	FASTA	file	should	represent	the	
most	representative	genome,	with	further	sequences	spanning	the	expected	interhost	diversity.	
Primal	Scheme	uses	the	Primer3	software	to	generate	candidate	primers	28.	This	chooses	
primers	based	on	highly	accurate	thermodynamic	modeling	to	take	into	account	length,	
annealing	temperature,	%GC,	3’	stability,	estimated	secondary	structure	and	likelihood	of	
primer-dimer	formation	maximising	the	chance	of	a	successful	PCR	reaction.	Primers	are	
designed	with	a	high	annealing	temperature	within	a	narrow	range	(65-68°C)	which	allows	PCR	
to	performed	as	a	2-step	protocol	(95°C	denaturation,	65°C	combined	annealing	and	extension)	
for	highly	specific	amplification	from	clinical	samples	without	the	need	for	nested	primers.		
● Test	candidate	primers:	Subsequent	reference	genomes	in	the	file	are	used	to	help	choose	
primer	pairs	that	maximise	the	likelihood	of	successful	amplification	for	known	virus	diversity.	A	
 pairwise	semi-global	alignment	score	between	each	candidate	primer	and	reference	is	
calculated	to	ensure	the	most	‘universal’	candidate	primers	are	picked	for	the	scheme.	
Mismatches	at	the	3’	end	are	severely	penalised	due	as	they	have	a	disproportionate	effect	on	
the	likelihood	of	successful	extension	29,30.	The	pairwise	distances	are	summed,	and	the	
minimum	scoring	primer	pairs	are	selected.	
● Output	primer	pairs:	Output	files	include	a	table	of	primer	sequences	to	be	ordered,	a	BED	file	of	
primer	locations	used	subsequently	for	primer	trimming	and	a	schematic	of	the	primer	scheme.		
	
Multiplex	PCR	Protocol	
Next,	we	developed	a	multiplex	PCR	protocol	employing	novel	reaction	conditions;	specifically	low	
individual	primer	concentrations,	high	primer	annealing	temperatures	(>65°C)	and	long	annealing	times,	
which	allows	amplification	of	products	covering	the	whole	genome	in	two	reactions	(Figure	3).	In	
comparison	to	single-plex	methods,	this	dramatically	reduces	the	cost	of	reagents	and	minimises	
potential	sources	of	laboratory	error.	We	assign	alternate	target	genome	regions	to	one	of	two	primer	
pools,	so	that	neighbouring	amplicons	do	not	overlap	within	the	same	pool	(which	would	result	in	a	
short	overlap	product	being	generated	preferentially).	By	screening	reaction	conditions	based	on	
concentration	of	cleaned-up	PCR	products	and	specificity	as	determined	by	gel	electrophoresis,	we	
determined	that	lower	primer	concentrations	and	longer	annealing/extension	time	were	optimal.	Given	
the	low-cost	of	the	assay	this	step	could	also	be	performed	alongside	standard	diagnostic	qRT-PCR	as	a	
quality	control	measure	to	help	reveal	potential	false	positives	31.	
	
Sequencing	protocol	optimisations	
Optimised	library	preparation	methods	for	both	the	MinION	and	Illumina	MiSeq	platforms	are	provided,	
and	should	be	readily	adaptable	to	other	sequencing	platforms	if	required.	The	MinION	system	is	
preferred	when	portability	and	ease	of	setup	in	harsh	environments	is	important	5.	The	Illumina	
platform	is	more	suited	to	sequencing	very	large	numbers	of	samples,	due	to	greater	sequence	yields	
and	the	ability	to	barcode	and	accurately	demultiplex	hundreds	of	samples.	Both	platforms	employ	
ligation-based	methods	to	add	the	required	sequencing	adapters	and	barcodes.	For	the	MinION	we	
utilised	the	native	barcoding	kit	(Oxford	Nanopore	Technologies,	Oxford,	UK)	to	allow	up	to	12	samples	
to	be	sequenced	per	flowcell.	As	the	manufacturer’s	protocol	is	designed	for	6-8	kb	fragmented	genomic	
DNA	we	have	adjusted	the	input	mass	to	achieve	an	equivalent	number	of	moles	of	DNA	ends,	this	
improves	the	efficiency	of	barcode/adapter	ligation	and	improves	run	yields.	For	the	work	presented	
here	we	used	R9	or	R9.4	flowcells	(FLO-MIN105/FLO-MIN106)	and	the	2D	barcoded	library	preparation	
kit	(EXP-NBD002/SQK-LSK208).	The	protocol	is	also	compatible	with	the	current	1D	barcoded	library	
preparation	kit	(EXP-NBD103/SQK-LSK108).	Due	to	the	regular	revisions	of	the	kits	we	have	avoided	
including	any	specific	component	names	or	volumes,	be	sure	to	follow	the	appropriate	protocol	for	your	
chosen	kit	version.	For	the	MiSeq	platform	the	Agilent	SureSelectxt2	adaptors	and	Kapa	Hyper	library	
preparation	kit	was	used	and	allowed	up	to	96	samples	per	MiSeq	run.	Other	library	prep	kits	(e.g.	
Illumina	TruSeq)	and	dual-indexed	adaptors	could	also	be	used	on	the	MiSeq.	Depending	on	the	number	
of	reads	required,	the	number	of	samples	multiplexed,	and	the	performance	of	the	flowcell,	sequencing	
on	the	MinION	can	be	run	for	anything	from	a	few	minutes	up	to	72	hours.	Typically	2-4	hours	of	
 sequencing	is	sufficient	for	12	samples.	For	the	MiSeq	we	recommend	using	the	2	x	250	nt	read-length	
for	400	nt	amplicons,	which	takes	48	hours	to	complete.	
	
Bioinformatics	workflow	
A	bioinformatics	pipeline	consisting	of	primer	trimming,	alignment,	variant	calling,	and	consensus	
generation	is	made	available	for	both	Oxford	Nanopore	and	Illumina	platforms,	the	former	building	
upon	tools	previously	developed	for	Ebola	virus	sequencing	in	Guinea.	The	MinION	pipeline	is	freely-
available	with	components	developed	under	the	permissive	MIT	open	source	license	at	
https://github.com/zibraproject/zika-pipeline.	The	pipeline	runs	under	the	Linux	operating	system	and	is	
available	as	a	Docker	image	meaning	that	it	can	also	be	run	on	Mac	and	Windows	operating	systems.	
This	MinION	pipeline	can	process	the	data	from	raw	reads	to	consensus	sequences	on	the	instrument	
laptop	given	the	correct	primer	scheme	as	a	BED	file	and	sample	sheet	as	required	input	files.	
	
MinION	pipeline	
FAST5	reads	containing	signal-level	information	may	be	basecalled	in	real-time	using	MinKNOW	or	
offline	using	Albacore.	Albacore	is	a	recurrent	neural	network	(RNN)	basecaller	developed	by	Oxford	
Nanopore	Technologies	and	made	available	through	the	MinION	Community	Portal.	The	resulting	FASTA	
files	are	demultiplexed	by	a	script	demultiplex.py	into	separate	FASTA	files	for	each	barcode,	as	
specified	in	a	config	file.	By	default	these	are	set	to	the	barcodes	NB01-12	from	the	native	barcoding	kit.	
Alternatively,	the	Metrichor	online	service	may	be	used	to	basecall	read	files	and	demultiplex	samples.	
Each	file	is	then	mapped	to	the	reference	genome	using	bwa mem	using	the	-x	ont2d	flag	and	
converted	to	BAM	format	using	samtools view.	Alignments	are	preprocessed	using	a	script	that	
performs	primer	trimming	and	coverage	normalisation.	Primer	trimming	is	performed	by	reference	to	
the	expected	coordinates	of	sequenced	amplicons,	and	therefore	requires	no	knowledge	of	the	
sequencing	adaptor	(Figure	3).	Signal-level	events	are	aligned	and	variants	are	called	using	
nanopolish variants. Low	quality	or	low	coverage	variants	are	filtered	out	and	consensus	
sequences	are	generated	using	a	script	margin_cons.py. Variant	calls	and	frequencies	can	be	
visualised	using	vcfextract.py	and	pdf_tree.py.		
	
Illumina	Pipeline	
First,	we	use	Trimmomatic	32	to	remove	primer	sequences	(first	22	nt	from	the	5’	end	of	the	reads)	and	
bases	at	both	ends	with	Phred	quality	score	<20.	Reads	are	aligned	to	the	genome	of	a	Zika	virus	isolate	
from	the	Dominican	Republic,	2016	(GenBank:	KU853012)	using	Novoalign	v3.04.04	
(http://www.novocraft.com/support/download/).	SAMtools	is	used	to	sort	the	aligned	BAM	files	and	to	
generate	alignment	statistics	33.	The	code	and	reference	indexes	for	the	pipeline	can	be	found	at	
https://github.com/andersen-lab/zika-pipeline.	Snakemake	is	used	as	the	workflow	management	
system	34.		
	
Alignment-based	consensus	generation	
We	have	used	an	alignment	based	consensus	approach	to	generate	genomes	as	opposed	to	de	novo	
assembly.	Although	de	novo	assembly	could	in	theory	be	used	with	this	protocol,	the	use	of	a	tiling	
 amplicon	scheme	already	assumes	the	viral	genome	is	present	in	a	particular	fixed	order.	This	
assumption	may	be	violated	in	the	presence	of	large-scale	recombination.	Some	de	novo	assemblers,	
such	as	SPAdes,	employ	a	frequency-based	error	correction	preprocessing	stage,	and	this	may	result	in	
primer	sequences	being	artificially	introduced	into	the	reference	if	primer	sequences	are	not	removed	in	
advance	35.	Importantly,	when	we	compared	alignment	to	de	novo-based	analysis	methods	of	our	
generated	Zika	virus	genomes,	we	found	that	we	always	obtained	the	same	consensus	sequences.	
	
Preparing	Sequencing	Controls	
We	recommend	positive	sample	controls	are	included	in	each	sequencing	run.	In	order	to	check	that	the	
protocol	is	generating	expected	results	we	recommend	choosing	a	positive	sample	with	an	established,	
trusted	reference	sequence.	For	Zika	virus,	we	used	the	previously	sequenced	World	Health	
Organization	reference	strain	PF13/251013-18	(Genbank	accession:	KX369547)	which	can	be	obtained	
on	request	from	the	Paul-Ehrlich-Institut	36,37.	Sample	archives	such	as	the	National	Collection	of	
Pathogenic	Viruses	(NCPV)	in	the	United	Kingdom	can	provide	high	quality	reference	materials	for	other	
viruses.	Positive	controls	should	have	similar	viral	copy	numbers	to	the	clinical	samples	on	the	same	run.	
This	may	require	the	positive	control	to	be	heavily	diluted	until	the	Ct	values	are	comparable.	Negative	
sequencing	controls	should	be	processed	in	as	similar	way	as	possible	as	clinical	samples	and	should	not	
be	simply	water	controls;	for	example	if	samples	are	collected	by	swabs,	then	the	same	type	of	unused	
swab	should	be	subjected	to	RNA	extraction	and	PCR.	Additional	negative	water	controls	may	be	added	
at	each	step	(e.g.	reverse	transcription,	PCR,	and	library	preparation)	to	detect	the	sources	of	
contaminants.	Even	if	amplification	is	not	detected	(e.g.	by	gel	electrophoresis),	or	if	DNA	quantity	is	low	
or	undetectable	by	fluorimetry,	a	sequencing	library	should	still	be	prepared	as	normal	using	the	total	
available	amount,	as	contamination	may	still	be	detectable	by	sequencing.	
	
A	Note	on	Contamination	
Cross-contamination	is	a	serious	potential	problem	when	working	with	amplicon	sequencing.		
Contamination	risk	is	minimised	by	maintaining	physical	separation	between	pre-	and	post-PCR	areas,	
and	performing	regular	decontamination	of	work	surfaces	and	equipment,	e.g.	by	UV	exposure	or	with	
1%	sodium	hypochlorite	solution.	Contamination	becomes	harder	to	mitigate	against	as	the	viral	load	in	
a	sample	reduces.	Processing	high	viral	count	samples	(e.g.	post-isolation)	can	increase	the	risk	of	
amplicon	‘bleed-over’	into	subsequent	low	viral	count	samples.	When	determining	how	many	PCR	cycles	
to	use,	begin	with	a	lower	number	and	increase	gradually	to	avoid	generating	excessive	quantities	of	
amplicons	making	physical	separation	harder.		
	
The	best	safeguard	to	help	detect	contamination	is	the	use	of	negative	controls.	These	controls	should	
be	sequenced	even	if	no	DNA	is	detected	by	quantification	or	no	visible	band	is	present	on	a	gel.	
Negative	control	samples	should	be	analysed	through	the	same	software	pipeline	as	the	other	samples.	
The	relative	number	of	reads	compared	with	positive	samples	give	a	simple	guide	to	the	extent	of	
contamination,	and	inspection	of	coverage	plots	demonstrates	can	help	determine	whether	a	specific	
region	is	involved,	and	potentially	its	origin	by	reference	to	the	sequence.	
	
Comparison	with	other	approaches	
 The	three	most	common	approaches	for	sequencing	viruses	are	metagenomic	sequencing,	PCR	
amplification	sequencing	and	target	enrichment	sequencing,	recently	reviewed	in	detail	by	Houldcroft	et	
al.	38.	The	main	benefit	to	the	PCR	based	approach	described	here	is	cost	and	sensitivity.	In	theory	both	
PCR	and	cell	culture	require	only	one	starting	molecule/virion,	making	them	both	exquisitely	sensitive.	
In	practice,	however,	the	reaction	conditions	do	not	allow	single-genome	amplification	and	typically	a	
number	of	starting	molecules	are	required.	PCR	also	has	limited	sensitivity	in	cases	where	the	template	
sequence	is	divergent	from	the	expected	due	to	primer	binding	kinetics.	This	makes	it	more	suitable	for	
use	in	an	outbreak	situation	where	isolates	are	highly	related	and	low	cost	per	sample	and	rapid	
turnaround	time	are	required.	Sequencing	amplicons	is	a	popular	method	to	determine	viral	genomes	
on	the	Oxford	Nanopore	MinION	and	has	been	used	for	diverse	viruses	including	Ebola,	influenza	and	
poxvirus	using	either	single	primer	pair	reactions	generating	long	amplicons	(>1	kb),	or	multiple	
reactions	pooled	before	sequencing	5,39–41.	However,	these	approaches	are	laborious	to	scale	up	when	
many	small	amplicons	are	required	(due	to	low	viral	copy	numbers),	or	when	multiple	samples	are	
sequenced	on	a	single	sequencing	run,	as	in	this	protocol.	
	
The	most	similar	alternative	approach	to	the	one	described	here	is	AmpliSeq	(Life	Technologies).	
However,	this	protocol	is	specific	to	the	Ion	Torrent	platform	and	primer	schemes	must	be	ordered	
directly	from	the	manufacturer,	and	is	consequently	more	expensive	per	sample.	Alternative	software	to	
design	primer	schemes	is	available,	some	of	which	cater	specifically	for	multiplex	or	tiling	amplicon	
schemes	20,21,42,43,	and	these	may	perform	better	when	dealing	with	divergent	genomes	due	to	an	
increased	emphasis	on	oligonucleotide	degeneracy.	Primers	generated	with	such	software	may	also	be	
compatible	with	this	protocol,	although	PCR	conditions	may	require	optimisation.	In	contrast,	Primal	
Scheme	is	designed	with	an	emphasis	on	monitoring	short-term	evolution	of	known	lineages	and	primer	
conditions	have	been	optimised	for	multiplex	PCR	amplification	efficiency.	
	
Propagation	with	cell	culture	has	been	widely	used	for	virus	enrichment	44–46.	This	process	is	time-
consuming,	requires	specialist	expertise,	and	requires	high	containment	laboratories	for	especially	
dangerous	pathogens.	There	is	also	concern	that	viral	passage	can	introduce	mutations	not	present	in	
the	original	clinical	sample,	potentially	confounding	analysis	47,48.		
	
Oligonucleotide	bait	probes	have	also	shown	promise	as	an	alternative	to	metagenomics	and	amplicon	
sequencing	49–53.	This	method	fishes	for	viral	nucleic	acid	sequences	by	hybridising	target-specific	
biotinylated	probes	to	the	DNA/RNA	sample	then	pulls	them	down	using	magnetic	streptavidin	beads.	
These	methods,	however,	are	limited	by	the	efficiency	of	the	capture	step	due	to	the	kinetics	of	nucleic	
acid	hybridisation	in	complex	samples,	such	as	those	containing	the	human	genome.	The	complete	
hybridisation	of	all	probes	to	targets	can	take	hours	(typical	protocols	suggest	a	24	h	incubation,	
although	shorter	times	may	be	possible)	and	may	never	be	achieved	due	to	competitive	binding	by	the	
host	DNA.	These	methods	suffer	from	a	coverage	bias	which	worsens	at	lower	viral	abundances	
resulting	in	increasingly	incomplete	genomes,	as	demonstrated	by	recent	work	on	Zika	virus	54.	These	
methods	work	best	on	higher	abundance	samples,	and	may	not	have	the	sensitivity	to	generate	near-
complete	genomes	for	the	majority	of	isolates	in	an	outbreak.	Probes	for	hybridisation	capture	are	more	
 expensive	than	PCR	primers	because	they	are	usually	designed	in	a	fully-overlapping	75	nt	scheme	which	
can	run	to	hundreds	of	probes	per	virus	and	thousands	for	panels	of	viruses.	
	
Direct	sequencing	of	RNA	has	been	recently	demonstrated	on	the	Oxford	Nanopore	MinION	55,56.	This	
method	is	attractive	because	it	eliminates	the	need	for	reverse	transcription,	and	so	potentially	may	
reduce	biases	resulting	from	non-random	priming,	and	copying	errors	introduced	by	reverse	
transcriptase.	However,	currently	this	method	requires	500	ng	of	RNA	as	starting	material	and	would	
suffer	from	the	same	sensitivity	issues	associated	with	cDNA	metagenomics	approaches	when	applied	to	
samples	containing	very	low	viral	copy	numbers.	
	
MATERIALS	
REAGENTS	
Tiling	amplicon	generation	
Clinical	sample	(serum,	plasma,	urine)	or	isolate	CAUTION	Any	potentially	infectious	clinical	samples	should	be	
handled	and	made	safe	in	accordance	with	biosafety	regulations.	If	unsure,	contact	your	local	safety	officer.	
CAUTION	Please	follow	local	institutional	review	board	guidelines	covering	the	collection	and	storage	of	clinical	
samples	for	research	purposes.	This	study	has	been	evaluated	and	approved	by	Institutional	Review	Boards	at	The	
Scripps	Research	Institute	and	relevant	local	IRBs	in	Colombia	and	Brazil	for	Zika	and	chikungunya	sample	
collection	and	sequencing.	
QIAamp	Viral	RNA	Mini	Kit	(Qiagen,	cat.	no.	52906)	CAUTION	Please	consult	MSDS	document	for	safety	
information	on	specific	kits	
Random	Hexamers	(50	µM)	(Thermo	Fisher,	cat.	no.	N8080127)	
Protoscript	II	First	Strand	cDNA	Synthesis	Kit	(NEB,	cat.	no.	E6560)	
Deoxynucleotide	(dNTP)	Solution	Mix	(NEB,	cat.	no.	N0447)	
Q5	Hot	Start	High-Fidelity	DNA	Polymerase	(NEB,	cat.	no.	M0493)	CRITICAL	The	primer	annealing	temperatures	are	
optimised	for	these	reagents.	Whilst	others	may	work,	thermocycling	conditions	may	need	to	be	optimised.	
PCR	primers	are	listed	in	Supplementary	Table	1	and	Table	2	(Integrated	DNA	Technologies)	
Agencourt	AMPure	XP	(Beckman	Coulter,	cat.	no.	A63881)	
Qubit	dsDNA	HS	Assay	Kit	(Thermo	Fisher,	cat.	no.	Q32854)	
HyPure	Molecular	Biology	Grade	Water	(GE	Life	Sciences,	cat.	no.	SH30538.01)	
EB	buffer	(10	mM	Tris-Cl,	pH	8.5)	
TE	buffer	(10	mM	Tris-Cl	pH	8.0,	0.1	mM	EDTA)	
Ethanol,	absolute	(Thermo	Fisher,	cat.	no.	BP28184)		
	
Gel	Electrophoresis	
Gel	Loading	Dye,	Purple	(6X)	(NEB,	cat.	no.	B7024)	
100	bp	DNA	Ladder	(NEB,	cat.	no.	N3231)	
SeaKem	LE	Agarose	(Lonza,	cat.	no.	5000)	
10X	TBE	Buffer	(Lonza,	cat.	no.	50843)	
SYBR	Safe	DNA	Gel	Stain	(Thermo	Fisher,	cat.	no.	S33102)	
	
MinION	sequencing	
MinION	Flow	Cell	(Oxford	Nanopore	Technologies,	cat.	no.FLO-MIN106)	
Nanopore	Sequencing	Kit		(Oxford	Nanopore	Technologies,	cat.	no.	SQK-LSK108)	
Native	Barcoding	Kit	(Oxford	Nanopore	Technologies,	cat.	no.	EXP-NBD103)	
 NEBNext	Ultra	II	End-repair/dA-tailing	Module	(NEB,	cat	no.	E7546)	
NEB	Blunt/TA	Ligase	Master	Mix	(NEB,	cat	no.	M0367)	
	
MiSeq	sequencing	
KAPA	Hyper	Library	Prep	(Roche,	cat.	no.	07962363001)	
SureSelectxt2	indexes,	MSQ,	16	(Agilent,	cat.	no.	G9622A)	
MiSeq	Reagent	Kit	v2	(500	cycle)	(Illumina,	cat.	no	MS-102-2003)	
D1000	ScreenTape	(Agilent,	cat.	no.	5067-5582)	
D1000	Reagents	(Agilent,	cat.	no.	5067-5583)	
KAPA	Library	Quantification	Kit	for	Illumina	platforms	(Roche,	cat.	no	07960140001)	
 
EQUIPMENT	
Filtered	pipette	tips	
1.5	ml	microcentrifuge	tube	(Eppendorf,	cat.	no.	0030	108.051)	
0.2	ml	strip	tubes	with	attached	caps	(Thermo	Fisher,	cat.	no	AB2000)	
UV	spectrophotometer	(Thermo	Fisher	NanoDrop	2000,	cat.	no.	ND-2000)	
96-well	thermocycler	(Applied	Biosystems	Veriti,	cat.	no.	4375786)	
Benchtop	microcentrifuge	(Thermo	Fisher	mySPIN	6,	cat.	no.	75004061)	
Benchtop	heater/shaker	(Eppendorf	ThermoMixer	C)	
Magnetic	rack	(ThermoFisher	DynaMag-2,	cat.	no.	12321D)	
PCR	cabinet	or	pre-PCR	room	
	
MinION	sequencing	
MinION	(Oxford	Nanopore	Technologies	cat.	no.	MinION	Mk1B)	
Laptop	with	solid	state	disk	(SSD)	drive	
	
MiSeq	sequencing	
MiSeq	(Illumina)	
TapeStation	2200	(Agilent)	
	
Gel	Electrophoresis	
Mini-Sub	Cell	GT	(Bio-Rad,	cat.	no.	1704406)	
PowerPac	Universal	Power	Supply	(Bio-Rad,	cat.	no.	1645070)	
	
PROCEDURE	
Design	and	ordering	of	primers	TIMING	1	h	
1|	(Optional)	Identify	representative	reference	sequences	(e.g.	from	public	databases	such	as	GenBank)	
and	generate	a	primer	scheme	using	Primal	Scheme	by	visiting	primal.zibraproject.org.	Choose	an	
amplicon	length	that	is	suitable	for	your	sequencing	platform,	and	likely	viral	copy	number	of	your	
sample	(e.g.	300-500	nt	for	Zika	on	MinION/Illumina).	
	
2|	Order	the	primers	generated	by	the	online	tool	or	from	the	pre-designed	schemes	provided	in	the	
Supplementary	Table	1	and	2	from	your	oligonucleotide	supplier.	Primers	can	be	ordered	pre-diluted	in	
TE	to	100	µM	(usually	at	addition	cost)	to	avoid	manually	resuspending	large	number	of	primers.	
	
 Extraction	of	nucleic	acids	and	preparation	of	cDNA	if	required	TIMING	1-2	h	
3|	Tiling	amplification	is	a	general	technique	which	can	be	applied	to	DNA	or	cDNA	generated	from	RNA	
by	reverse	transcription.	Follow	the	appropriate	instructions	for	your	application.	
	(A)	RNA	extraction	and	preparation	of	cDNA	for	RNA	viruses	
(i)	Extract	RNA	from	200	µl	of	either	serum,	plasma	or	urine	using	the	QIAamp	Viral	RNA	
Mini	Kit	according	to	the	manufacturer’s	instructions	eluting	in	50	µl	EB	buffer.	
(ii)	Measure	the	absorption	spectra	using	a	spectrophotometer.	Pure	RNA	should	have	a	
260/280	ratio	of	2.0	and	a	260/230	ratio	of	2.0-2.2.	
TROUBLESHOOTING	
(iii)	Perform	the	following	two	steps	in	a	hood	or	dedicated	pre-PCR	area.	Wash	all	
surfaces	with	1%	sodium	hypochlorite	solution	and	irradiate	labware	with	UV	light	for	at	
least	10	minutes.	Sample	negative	controls	for	each	primer	pool	should	be	included	on	
each	PCR	run.	
CRITICAL	STEP	
(iv)	Mix	the	following	in	a	0.2	ml	tube.	This	denaturation	step	minimises	secondary	
structure	in	the	RNA	prior	to	cDNA	synthesis.	
	
Component	 	 	 Amount	(µl)	 Final	concentration	
Template	RNA	 	 	 7	 	
Random	hexamers,	50	µM	 1	 	 2.5	µM	
	
(v)	Denature	the	template	RNA	by	incubating	on	a	heat	block	at	65	°C	for	5	minutes	
before	placing	promptly	on	ice.	
(vi)	Complete	the	cDNA	synthesis	reaction	by	adding	the	following	to	the	tube:	
	
Component	 	 	 Amount	(µl)	 Final	concentration	
ProtoScript	II	Reaction	Mix	(2x)	 10	 	 1x	 	
ProtoScript	II	Enzyme	Mix	(10x)	 2	 	 1x	
	
(vii)	Place	on	a	thermocycler	and	run	the	following	program:	
	
Cycle	number	 Condition	
1	 	 25	°C,	5	min	
1	 	 48	°C,	15	min	
1	 	 80	°C,	5	min	
	
(B)	DNA	extraction	for	DNA	viruses	
(i)	Extract	DNA	from	200	µl	of	either	serum,	plasma	or	urine	using	the	QIAamp	MinElute	
Virus	Spin	Kit.	
(ii)	Measure	the	absorption	spectra	using	a	spectrophotometer.	Pure	DNA	should	have	a	
260/280	ratio	of	1.8	and	a	260/230	ratio	of	2.0-2.2.	
TROUBLESHOOTING	
 	
Preparing	the	primer	pools	TIMING	1	h	
4|	To	resuspend	lyophilised	primers,	pre-spin	tubes	to	make	sure	pellet	is	at	the	bottom	of	the	tube	and	
add	TE	to	a	concentration	of	100	µM.	The	volume	of	TE	to	give	100	µM	is	often	given	on	the	QC	
document	supplied	with	the	primer.	If	they	are	already	pre-diluted	to	100	µM	continue	to	the	next	step.	
	
5|	Label	two	1.5	ml	Eppendorf	tubes	using	the	scheme	and	pool,	either	‘1’	or	‘2’.	Add	an	equal	volume	
of	each	100	µM	primer	stock	such	that	both	the	forward	and	reverse	primer	for	alternate	regions	are	
pooled	together.	For	example.	Pool	‘1’	for	ZikaAsian	scheme	would	contain	ZIKA_400_1_LEFT,	
ZIKA_400_1_RIGHT,	ZIKA_400_3_LEFT,	ZIKA_400_3_RIGHT,	ZIKA_400_5_LEFT,	ZIKA_400_5_RIGHT	etc.	Dilute	
these	1:10	to	a	working	concentration	of	10	µM.	
	
Performing	multiplex	tiling	PCR	TIMING	5	h	
6|	In	Eppendorf	tubes	prepare	a	mastermix	for	each	of	the	primer	pools	1	and	2.	Mix	thoroughly	by	
vortexing	and	spin	down	in	a	microfuge.	Label	0.2	mL	PCR	tubes	and	add	22.5	µl	(if	using	2.5	µl	cDNA)	
mastermix	to	each	tube.	A	master	mix	including	10%	excess	volume	is	used	for	setting	up	PCR	as	it	
reduces	variability	between	reactions.	The	volume	of	primers	to	use	will	depend	on	the	number	of	
primers	in	the	pool	as	the	final	concentration	should	be	0.015	µM	per	primer.	For	example	the	ZikaAsian	
scheme	from	Supplementary	Table	1	has	36	primers	in	pool	1	so	the	volume	to	use	would	be	1.35	µl.	
	
Component	 	 	 Amount	(µl)	 Final	concentration	
Q5	reaction	buffer	(5x)	 	 5	 	 1x	
dNTPs,	10	mM	 	 	 0.5		 	 200	µM	
Q5	DNA	polymerase	 	 0.25	
Primer	pool	1	or	2	(10	µM)	 Varies	 	 0.015	µM	per	primer		
PCR	grade	water	 	 Varies	
	
7|	Add	2.5	ul	cDNA	from	step	3(A)(vii)	to	each	tube.	It	is	recommended	that	cDNA	volume	be	kept	to	
10%	of	the	final	volume	of	PCR	reaction	to	avoid	significantly	affecting	the	buffer	conditions.	If	you	are	
using	extracted	DNA	from	step	3(B),	a	larger	volume	be	added	if	required.	This	step	should	ideally	be	
performed	cabinet	used	only	for	template	addition	to	minimise	risk	of	amplicon	contamination.	
	
8|	Place	on	a	thermocycler	run	the	following	program:	
	
Cycle	number	 Denature	 Anneal/extend	
1	 	 98	°C,	30	s	
2-40	 	 98	°C,	15	s	 65	°C,	5	m	
	
Cleanup	and	quantification	of	amplicons	TIMING	1	h	
9|	Transfer	contents	of	the	tube	to	a	1.5	ml	Eppendorf	tube.	Add	the	volume	of	SPRI	beads	given	in	the	
table	below	taking	into	account	amplicon	length.	Perform	washes	following	the	instructions	in	the	1D	
barcoding	protocol	and	elute	in	30	µl	nuclease-free	water	or	EB.	
 	
Amplicon	length	 Ratio	 Volume	of	beads	in	µl	(assumes	25	µl	PCR	reaction)	
<500	 	 	 1.0x	 25	
500-1000	 	 0.8x	 20	
>1000	 	 	 0.6x	 15	
	
10|	Quantify	1	µl	of	the	cleaned	product	using	the	Qubit	with	the	high-sensitivity	assay	as	per	the	
manufacturer’s	instructions.	You	should	expect	concentrations	in	the	range	5	-	50	ng/µl	for	each	
reaction	from	the	Qubit	quantification,	except	the	PCR	negative	control	which	should	be	repeated	if	>1	
ng/µl.	
TROUBLESHOOTING	
	
11|	(Optional)	Make	a	gel	by	melting	1%	(w/v)	agarose	powder	in	1X	TBE	then	adding	1X	SYBR	Safe	gel	
stain	before	allowing	it	to	set.	Place	in	a	gel	tank	submerged	in	1X	TBE.	Mix	10	µl	cleaned	product	or	
ladder	with	2	µl	6x	loading	dye	and	load	on	the	gel.	Perform	electrophoresis	at	6	V/cm	until	bands	are	
distinguishable	by	transillumination.		A	specific	band	of	the	correct	size	for	your	scheme	should	be	
observed.		
TROUBLESHOOTING	
	
Library	preparation	and	sequencing	TIMING	Up	to	1-2	d	
12|	Library	preparation	and	sequencing	are	platform	specific	and	and	have	been	validated	on	the	
MinION	from	Oxford	Nanopore	Technologies	and	on	the	MiSeq	from	Illumina.	
(A) Library	preparation	and	sequencing	using	the	MinION	
(i)	Number	of	samples	per	flowcell.	We	recommend	using	two	barcodes	per	
sample	or	negative	control	(one	barcode	per	pool	per	sample)	initially.	This	
makes	it	easier	to	detect	contamination	that	may	be	pool-	rather	than	sample-
specific.	However	a	single	barcode	per	sample	can	also	be	used	to	maximise	the	
number	of	samples	per	flowcell.	
(ii)	Normalisation.	Use	the	table	below	to	determine	the	quantity	of	amplicons	
to	load	to	achieve	a	total	input	of	~0.3	pM.	The	total	quantity	must	be	divided	
by	the	number	of	barcodes	being	used	to	calculate	the	quantity	per	barcode.	
PCR	products	should	be	kept	separate	at	this	stage,	and	the	appropriate	volume	
added	to	individual	1.5	ml	Eppendorf	tubes.	The	volume	in	each	Eppendorf	is	
then	adjusted	to	20	µl	with	nuclease-free	water.	
	
Scheme	length	 	 Input	total	(ng)	
300	 	 	 60	
400	 	 	 80	
500	 	 	 100	
1000	 	 	 200	
1500	 	 	 300	
2000	 	 	 400	
 5000	 	 	 1000	
	
TROUBLESHOOTING	
(iii)	End-repair	and	dA-tailing.	For	each	sample	setup	the	following	end-
repair/dA-tailing	reaction	in	a	1.5	ml	Eppendorf	tube	and	incubate	for	5	minutes	
at	20°C	followed	by	5	minutes	at	65°C.	Perform	a	SPRI	cleanup	as	per	step	9,	
eluting	each	in	10	µl	nuclease-free	water	or	EB.	
	
Component	 	 	 	 Amount	(µl)	
Amplicons	 	 	 	 20	
Ultra	II	End	Prep	Reaction	Buffer	 2.8	
Ultra	II	End	Prep	Enzyme	Mix	 	 1.2	
	
(iv)	Barcode	ligation.	In	a	1.5	ml	Eppendorf	prepare	the	following	ligation	
reactions,	one	reaction	per	barcode	being	used.	
	
Component	 	 	 Amount	(µl)	
dA-tailed	amplicons	 	 10	
Native	barcode	NB01-NB12	 2.5	
Blunt/TA	Ligase	Master	Mix	 12.5	
	
(v)	Incubate	at	room	temperature	for	10	minutes	followed	by	65°C	for	10	
minutes	to	denature	the	ligase.	
(vi)	Pool	barcoded	amplicons.	Combine	all	the	barcode	ligation	reactions	into	a	
single	1.5	ml	Eppendorf	tube.	Perform	cleanup	as	before	using	the	ratio	of	SPRI	
beads	used	previously	and	elute	in	30	µl	nuclease-free	water.	If	the	pellet	is	
large	you	can	speed	up	drying	by	briefly	incubating	at	50°C,	do	not	allow	the	
pellet	to	overdry	and	crack	or	recovery	will	be	reduced.	
(vii)	Barcoding	adapter	ligation.	In	a	1.5	ml	Eppendorf	tube	prepare	the	adapter	
ligation	reaction	according	to	the	native	barcoding	protocol.	We	have	found	
that	using	Blunt/TA	Ligase	instead	of	the	NEBNext	Quick	Ligation	Module	as	
described	in	the	protocol	improves	the	efficiency	of	this	step.	As	this	is	a	2X	
master	mix	we	have	adjusted	the	elution	volume	in	the	previous	step	to	
accommodate	this.		
(viii)	Library	cleanup	and	elution.	Complete	library	construction	according	to	the	
native	barcoding	protocol.	In	the	last	step	elute	the	library	in	14.5	ul	and	use	the	
whole	volume	when	preparing	the	library	dilution.	
(ix)	Library	loading.	Perform	library	loading	and	sequencing	according	to	the	
manufacturer’s	instructions.	If	the	siphon	action	of	the	SpotON	flowcell	stops	
while	loading	library,	push	a	little	air	into	the	inlet	port	using	the	volume	
adjustment	screw	of	a	pipette	then	back	it	out	again	and	resume	loading.	
TROUBLESHOOTING	
 (x)	Start	sequencing	run.	By	default	you	will	need	an	internet	connection	before	
the	sequencing	script	can	be	started,	although	completely	offline	versions	of	
MinKNOW	may	be	available	from	the	manufacturer	on	request.	Once	the	
flowcell	is	detected	enter	an	experiment	name	and	the	flowcell	into	the	blank	
fields	then	choose	the	appropriate	sequencing	script	for	the	library	preparation	
kit	and	flowcell	version.	If	a	‘Live’	basecalling	script	is	run,	reads	will	be	
basecalled	in	real-time.	If	you	do	this	then	you	need	to	remember	to	skip	this	
step	when	running	the	analysis	pipeline	later.		
(B)	Library	preparation,	sequencing	and	analysis	using	the	MiSeq.	
(i)	Number	of	samples	per	flowcell.	We	recommend	using	two	barcodes	per	
sample	which	means	up	to	47	samples	plus	a	negative	control	can	be	sequenced	
on	each	run	and	allows	each	pool	to	be	barcoded	individually.	This	makes	it	
easier	to	detect	contamination	that	may	be	pool	rather	than	sample	specific.	It	
also	results	in	greater	yield	per	sample	which	improves	genome	coverage	in	
samples	with	more	uneven	amplification.	
(ii)	Normalisation.	Keeping	pools	in	individual	1.5	ml	Eppendorf	tubes	add	50	ng	
material	and	add	nuclease-free	water	to	adjust	total	volume	to	50	µl.	
(iii)	End-repair	and	dA-tailing.	Perform	end-repair	and	dA-tailing	according	to	
the	Hyper	prep	kit	protocol	(KAPA).	
(iv)	Library	preparation.	Complete	library	construction	with	the	KAPA	Hyper	
Prep	Kit	according	to	the	manufacturer's	instructions	substituting	the	KAPA	
Adapters	for	SureSelectxt2	Indexing	Adaptors	in	the	adapter	ligation	step.	A	0.8X	
instead	of	1X	SPRI	cleanup	should	be	performed	during	the	post-amplification	
cleanup	to	remove	potential	adaptor-dimers.	
(v)	Library	quality	control.	Measure	the	size	distribution	of	the	library	using	the	
TapeStation	2200	according	the	manufacturer’s	instructions.	
(vi)	Library	pooling.	Calculate	the	molarity	of	each	library	using	the	KAPA	Library	
Quantification	according	to	the	manufacturer's	instructions	and	pool	libraries	in	
an	equimolar	fashion.	
(vii)	Library	dilution	and	loading.	Prepare	library	for	loading	onto	the	MiSeq	
according	to	the	manufacturer’s	instructions.	
(viii)	Basecalling	and	demultiplexing.	Basecalling	and	demultiplexing	will	be	
performed	automatically	on	the	instrument	if	the	sample	sheet	is	provided	
when	starting	the	run.	
	
Data	analysis	TIMING	1-2	h	
13|	Download	Docker	application	for	Linux,	Mac	or	Windows	from	
(https://www.docker.com/products/overview).	Run	the	installer	to	setup	the	docker	tools	on	your	
machine.	You	should	now	be	able	to	open	a	terminal	window	and	run	the	command	docker --
version without	getting	an	error.	The	source	code	of	the	pipeline	is	also	available	via	The	Zika	
analysis	pipeline	is	available	from	https://github.com/zibraproject/zika-pipeline.			
 14|	Download	the	Zika	pipeline	image	from	DockerHub	by	typing	docker pull zibra/zibra 
into	the	terminal	window.	The	Zika	pipeline	is	compatible	with	both	MinION	data	and	Illumina	data	yet	
there	are	some	differences	in	the	data	handling	required.	
15|	Start	a	Docker	container	with	the	following	command.	To	test	the	container	is	working,	run:	
docker run -t -i zibra/zibra:latest 
Docker	containers	do	not	have	access	to	the	file	system	of	the	computer	they	run	within	by	default.	You	
will	need	to	provide	access	to	a	local	directory	in	order	to	see	data	files.	This	is	achieved	using	the	-v	
parameter.	You	may	need	to	grant	access	to	Docker	to	share	the	drive	via	the	Shared	Drives	menu	
option	under	Settings.	For	example,	on	Windows,	if	you	wished	to	provide	access	to	the	c:\data\reads	
directory	to	the	Docker	container,	use	the	following	
docker run -v c:/data/reads:/data -t -i zibra/zibra:latest /bin/bash 
Then,	within	the	Docker	container	the	/data directory	will	refer	to	c:\data\reads on	the	
Windows	machine.	
	
16|	Run	the	platform	specific	pipeline.	The	Zika	pipeline	is	compatible	with	both	MinION	data	and	
Illumina	data	yet	there	are	some	differences	in	the	data	handling	required.	
(A)	Running	analysis	pipeline	on	MinION	data.	
(i)	Ensure	the	reads	are	basecalled	using	either	Metrichor	or	an	offline	basecaller.	
Compatible	basecallers	including	Albacore	(available	as	installable	packages	for	Linux,	
Windows	and	Mac	through	the	MinION	Community	Portal)	or	and	the	freely-available	
and	open-source	nanonet	(https://github.com/nanoporetech/nanonet)	software.	
Nanonet	is	compatible	with	graphics	processing	unit	(GPU)	cards	to	increase	speed.	
(ii)	Metrichor	will	perform	demultiplexing	if	a	barcoding	workflow	is	selected.	For	other	
basecallers	you	may	need	to	demultiplex	reads	manually.	A	script	is	provided	within	the	
Docker	image	to	do	this,	which	is	run	with	the	command:	
demultiplex.sh <directory of FAST5 Files> <output directory> 
(iii)	Run	the	Zika	pipeline.	The	pipeline	takes	three	required	items	
sample_id --	the	sample	name	(should	not	contain	space	characters)	
directory	--	the	directory	containing	the	FAST5	files	for	a	single	sample	(e.g.	
demultiplexed	output	directory	from	previous	step)	
scheme	--	the	name	of	the	scheme	directory,	e.g.	ZikaAsian	
fast5_to_consensus.sh <scheme> <sampleID> <directory> 
For	example:	
fast5_to_consensus.sh ZikaAsian Zika1 /data/NB08/downloads/pass 
(iv)	Output	files	will	be	written	to	the	current	directory.	The	final	consensus	file	will	be	
named	<sampleID>.consensus.fasta 
(B)	Running	analysis	pipeline	on	Illumina	data.	
(i)	Download	and	follow	the	instructions	for	the	Illumina	pipeline	by	reference	to	
https://github.com/andersen-lab/zika-pipeline	
	 	 illumina_pipeline.sh <sampleID> <fastq1> <fastq2> <scheme> 
	 	
Quality	control	TIMING	1	h	
 17|	Check	the	coverage	of	the	genomes	by	reference	to	the	alignment	file.	Use	an	alignment	viewer	
such	as	IGV	57	or	Tablet	58	and	load	the <sampleID>.primertrimmed.sorted.bam	file	in	
conjunction	with	the	reference	sequence.	Amplicons	should	be	evenly	spread	throughout	the	genome.	
Deep	piles	of	reads	representing	amplification	of	single	regions	are	potentially	warning	signs	of	
contamination.	The	alignments	should	be	compared	with	the	positive	and	negative	control	alignments	
to	help	indicate	problematic	samples	or	regions.	
18|	The	Zika	pipeline	produces	a	variant	frequency	plot	to	help	determine	the	allele	frequency	of	
mutations	in	the	sample	(compared	with	the	reference).	The	variant	frequency	plot	is	given	the	name 
<sampleID>.variants.png	and	is	generated	from	the	<sampleID>.variants.tab	file	that	
can	be	opened	in	spreadsheet	applications	or	statistical	software.	The	principle	of	the	variant	frequency	
plot	is	to	identify	mutations	that	occur	at	lower	than	expected	allele	frequencies	and	help	decide	
whether	they	are	a	biological	phenomenon	(e.g.	intra-host	single	nucleotide	variants),	potential	signs	of	
contamination,	or	sequencing	errors	(for	example	in	homopolymeric	tracts	in	MinION	data).	
	
TROUBLESHOOTING	
Troubleshooting	advice	can	be	found	in	Table	4.	
	
TIMING	
Steps	1-2,	Design	and	ordering	of	primers:	1	h	
Step	3(A),	RNA	extraction,	QC	and	cDNA	synthesis:	2	h	
Step	3(B),	DNA	extraction	and	QC:	1	h	
Steps	4-5,	Preparing	the	primer	pools:	1	h	
Steps	6-8,	Performing	multiplex	tiling	PCR:	5	h	
Steps	9-11,	Cleanup	and	quantification	of	amplicons:	1	h	
Step	12,	Library	preparation	and	sequencing:	1-3	d	
Steps	13-17,	Data	analysis:	1-2	h	
Steps	18-19,	Quality	control	of	consensus	sequences:	1	h	
	
ANTICIPATED	RESULTS	
This	protocol	should	achieve	near-complete	genome	coverage.	
	
MinION	Sequencing	
As	a	demonstration	of	the	ZikaAsian	scheme	on	MinION	we	sequenced	the	World	Health	Organization	
Zika	reference	sample	11474/16	36	(Table	2)	and	a	chikungunya	clinical	sample	from	Brazil	PEI-N11602.	
The	Ct	value	for	the	Zika	virus	sample	was	between	18-20	depending	on	RNA	extraction	method	used.	
The	Ct	value	for	the	Chikungunya	sample	was	20	as	determined	by	the	RealStar®	Chikungunya	RT-PCR	
Kit	1.0	from	Altona	Diagnostics	(Hamburg,	Germany).	The	Zika	virus	sample	generated	97.7%	coverage	
of	the	genome	above	25x	coverage.	Coverage	of	the	genome	was	reasonably	even,	with	a	drop-out	in	
the	middle	of	the	genome	(Figure	4).	The	WHO	Control	Reference	MinION	dataset	is	available	from	the	
CLIMB	website	(https://s3.climb.ac.uk/nanopore/Zika_Control_Material_R9.4_2D.tar).	
	
Illumina	Sequencing	
 We	compared	metagenomic	sequencing	to	the	ZikaAsian	scheme	with	the	Illumina	MiSeq	protocol	using	
five	clinical	samples	of	Zika	from	Colombia.	Using	a	previously	described	method	for	metagenomics	
sequencing2,17,	only	a	small	percentage	(<	0.01%)	of	our	reads	aligned	to	Zika	virus	and	they	covered	
only	a	fraction	of	the	genome	(Table	1).	Using	the	ZikaAsian	scheme,	we	were	able	to	generate	high	
coverage	of	all	the	genomes	(Table	3).	Illumina	sequencing	reads	are	available	from	BioProject	
PRJNA358078	(https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA358078).	
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Table	1|	Results	of	metagenomic	sequencing	on	five	Zika-positive	clinical	samples	collected	from	
Columbia	in	January	2016	(unpublished	data,	contributed	by	Kristian	Andersen	and	Nathan	Grubaugh).	
Sample	 Ct	1	 GE/ul	RNA	2	 #	Reads	 #	ZIKV	reads	
3	
%	ZIKV	 %	Coverage	 Depth	
ZC188	 34	 36	 	1,929,030	 60	 0.003	 23.7	 1.4	
ZC192	 33.9	 39	 	2,073,344	 223	 0.011	 79.2	 5.0	
ZC199	 35.9	 10	 	1,612,686	 0	 0	 0	 0	
ZC204	 33.6	 48	 	1,966,651	 28	 0.001	 25.3	 0.5	
ZC207	 35.2	 16	 	1,445,414	 4	 0.000	 3.4	 0.1	
1	qRT-PCR	cycle	threshold	(Ct)	value	
2	Genome	copy	equivalents	(GE)	per	microlitre	calculated	from	Ct	value	and	standard	dilutions.	
3	Number	of	reads	aligning	to	a	Zika	virus	reference	genome	
	
Table	2|	Results	of	MinION	sequencing	after	barcode	demultiplexing	for	an	isolate	of	Zika	and	for	a	
clinical	sample	of	chikungunya	virus	(Zika	data	from	Faria	et	al.	23,	chikungunya	data	unpublished	
contributed	by	Sally	Baylis,	Josh	Quick	and	Nicholas	Loman).		
Sample	 Scheme	 Pore	 Ct	 #	reads	
(2D	pass)	
#	Aligned	
reads	
%	aligned	 %	coverage	
(>25x)	
Depth	
Zika	WHO	
Control	
Reference	
(11474/16)	
ZikaAsian	 R9.4	 18-20	 9,606	 9,528	 99.2	 97.7	 392	
Chikungunya		
PEI		N11602	
ChikAsian
ECSA	
R9.4	 20	 89,365	 88,527	 99.1	 88	 2,779	
	
Table	3|	Results	of	amplicon	scheme	sequencing	on	five	Zika-positive	clinical	samples	from	Colombia	
using	the	ZikaAsian	scheme	on	the	Illumina	MiSeq	(unpublished	data,	contributed	by	Kristian	Andersen	
and	Nathan	Grubaugh).		
 Sample	 Ct	1	 GE/ul	
RNA	2	
Reads	 ZIKV	reads	3	 %	ZIKV	 %	Coverage	 Depth	 Genbank	ID	
ZC188	 34	 36	 	1,114,568	 	760,976	 68.3	 98.3	 	29,395	 KY317936	
ZC192	 33.9	 39	 	1,246,644	 	795,474	 63.8	 98.4	 	30,396	 KY317937	
ZC199	 35.9	 10	 	2,772,457	 	379,064	 13.7	 93.4	 	14,848	 KY317938	
ZC204	 33.6	 48	 	1,065,517	 	751,872	 70.6	 99.7	 	29,003	 KY317939	
ZC207	 35.2	 16	 	939,820	 	506,821	 53.9	 96.7	 	19,478	 KY317940	
1	qRT-PCR	cycle	threshold	(Ct)	value	
2	Genome	copy	equivalents	(GE)	per	microlitre	calculated	from	Ct	value	and	standard	dilutions.	
3	Number	of	reads	aligning	to	a	Zika	virus	reference	genome	
 
Table	4	|	Troubleshooting	table.	
Step	 Problem	 Possible	reason	 Possible	solution	
1	 Primal	scheme	failed	to	
generate	a	full	scheme	
Using	a	short	amplicon	length	
can	results	in	no	suitable	
primers	due	to	local	sequence	
context	
Increase	the	amplicon	
length	and	retry	
3(A)(ii)	or	
3(B)	(ii)	
260/280	lower	than	2.0	
for	RNA	or	1.8	for	DNA	
Carryover	of	guanidinium	
thiocyanate	from	the	lysis	
buffer	
Repeat	extraction	using	
additional	washes	to	
remove	unwanted	salt	from	
the	column	
10	 No	amplification		 Sample	may	be	a	false	positive	 Repeat	qRT-PCR	to	confirm	
sample	is	positive	
10	 Poor	amplification	 RNA	may	be	degraded	by	
RNAses	in	sample	
(serum/plasma)	or	incorrect	
storage	
Avoid	freeze	thawing	of	
samples;	use	a	shorter	
amplicon	scheme	
10	 Amplification	in	negative	
control	
Amplicon	contamination	in	
PCR	set-up	area	
Wash	all	surfaces	with	1%	
sodium	hypochlorite	
solution	and	irradiate	
labware	with	UV	light	for	at	
least	10	minutes.	
10	 Amplification	in	one	pool	
only	
Suboptimal	primer	
concentration	
Check	reaction	was	set	up	
correctly;	repeat	failed	pool	
 and	adjust	the	primer	
concentration.	
11	 No	specific	band	on	gel	 Non-specific	amplification	of	
host	DNA	
Attempt	to	DNase	treat	the	
sample;	use	serum	or	
plasma.	
12A(ii)	 Insufficient	amplicons	to	
make	library	
Amplicon	concentration	
needed	is	higher	per	sample	
when	you	have	small	numbers	
of	samples	
Amplify	more	samples	to	
run	together;	5-10	is	
optimal.	
12A(ix)	 MinKNOW	fails	to	start	
script	
Problem	with	MinKNOW	
installation	
Reinstall	MinKNOW	from	
scratch	and	restart	script	
17	 Insufficient	reads	 Incorrect	molarity	library	or	
insufficient	active	pores	on	
flowcell	
Run	another	flowcell	and	
combine	data	
17	 Amplification	of	some	
regions	but	not	others	
Too	many	mismatched	bases	
in	primers	
Redesign	primers	using	a	
less	divergent	reference	
genome	
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Supplementary	Table	2:	List	of	PCR	primers	for	ChikAsianECSA	scheme	
	
 
Figure 1| Workﬂow for tiling amplicon sequencing on MinION/Illumina with associated protocol steps. 
1.
3(a)(i). 3(b).
3(a)(iv-vii).
6-8.
10.
12.
12.
13-16.
17.
  
Figure 2| ​ Overview of multiplex primer design using primal online primer design tool. (​a​) 
Submission box for online primer design tool. ( ​b​) Primer table of results. ( ​c ​) Schematic showing 
expected amplicon products for each pool in genomic context for the ZikaAsian and 
ChikAsianECSA schemes. 
 
 
Figure 3|​ Overview of multiplex tiling PCR and pooling. 5 Schematic showing the regions 
amplified in pool 1 (upper track) and 2 (lower track) intended overlap between pools. 9 
Products generated by pool 1 (left tube) and 2 (right tube) for hypothetical scheme shown in 
5. 12(A)(ii) Input amount is normalised based on number of samples and the scheme length, 
pool 1 and 2 products can be pooled at this stage (shown) or kept separate if you wish to 
barcode them individually. 12(A)(iv) products for each sample are then barcoded by ligation 
of a unique barcode. 12(A)(vi) all barcoded products are all pooled together before 
sequencing adapter ligation yielding a sequenceable library. 
 Figure 4| ​ Coverage plots for ZikaAsian scheme sequenced on MinION before (top panel) and after 
primer trimming and coverage normalisation (bottom panel). During the preprocessing step reads 
are trimmed using a BED file containing primer positions and read coverage is normalised. The 
coverage plot was produced using the Tablet genome viewer ​30​.  
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Supplementary Table 1 |​ Zika virus “ZikaAsian” scheme used by ZiBRA project generated by the 
Primal Scheme software ​15​. 
Name Sequence Pool 
ZIKA_400_1_LEFT GACAGTTCGAGTTTGAAGCGAAAG 1 
ZIKA_400_1_RIGHT AGTATGCACTCCCACGTCTAGT 1 
ZIKA_400_2_LEFT AAGAAAGATCTGGCTGCCATGC 2 
ZIKA_400_2_RIGHT TGATTCCAACCAGGTTTGCGAC 2 
ZIKA_400_3_LEFT AGATGACGTCGATTGTTGGTGC 1 
ZIKA_400_3_RIGHT TACGGTGACACAACCTCCATGT 1 
ZIKA_400_4_LEFT TCAGGTGCATAGGAGTCAGCAA 2 
ZIKA_400_4_RIGHT GGAGCCATGAACTGACAGCATT 2 
ZIKA_400_5_LEFT AGAACGTTAGTGGACAGAGGCT 1 
ZIKA_400_5_RIGHT TGTGCGTCCTTGAACTCTACCA 1 
ZIKA_400_6_LEFT TTGATTGTGAACCGAGGACAGG 2 
ZIKA_400_6_RIGHT CCATCTGTCCCTGCGTACTGTA 2 
ZIKA_400_7_LEFT TGAAGGGCGTGTCATACTCCTT 1 
ZIKA_400_7_RIGHT CGCCTCCAACTGATCCAAAGTC 1 
ZIKA_400_8_LEFT GGGAGAAGAAGATCACCCACCA 2 
ZIKA_400_8_RIGHT TTGACTGCTGCTGCCAATCTAC 2 
ZIKA_400_9_LEFT GCCTTAGGGGGAGTGTTGATCT 1 
ZIKA_400_9_RIGHT GAGTGGGCATTCCTTCAGTGTG 1 
ZIKA_400_10_LEFT ACGGTCGTTGTGGGATCTGTAA 2 
ZIKA_400_10_RIGHT GTGGGACTTTGGCCATTCACAT 2 
ZIKA_400_11_LEFT CAGCCGTTATTGGAACAGCTGT 1 
ZIKA_400_11_RIGHT CCTGGGCCTTATCTCCATTCCA 1 
ZIKA_400_12_LEFT CACTAAGGTCCACGTGGAGGAA 2 
ZIKA_400_12_RIGHT TATCAGCGCCAGATGAGCTACA 2 
ZIKA_400_13_LEFT TGGCAGTGCTGGTAGCTATGAT 1 
ZIKA_400_13_RIGHT AGAGAGAGGAGCATAAACCCCC 1 
ZIKA_400_14_LEFT CAATGGTTTTGCTTTGGCCTGG 2 
ZIKA_400_14_RIGHT TTTCCCATGTGATGTCACCTGC 2 
ZIKA_400_15_LEFT CCCTAGCGAAGTACTCACAGCT 1 
ZIKA_400_15_RIGHT TACACTCCATCTGTGGTCTCCC 1 
ZIKA_400_16_LEFT GTGGCATGAACCCAATAGCCAT 2 
ZIKA_400_16_RIGHT GCTCCAATGTCCCCATCCTTTG 2 
ZIKA_400_17_LEFT GTGGTCCATGGAAGCTAGATGC 1 
ZIKA_400_17_RIGHT CCTCTAAGGGCCTCCTCCATTT 1 
ZIKA_400_18_LEFT CTGTTGAGTGCTTCGAGCCTTC 2 
ZIKA_400_18_RIGHT TGGTGAGTTGGAGTCCGGAAAT 2 
ZIKA_400_19_LEFT TATGGATGAGGCCCACTTCACA 1 
ZIKA_400_19_RIGHT GCCATCAAGTATGACCGGCTTT 1 
ZIKA_400_20_LEFT GGCTGGAAAACGGGTCATACAG 2 
ZIKA_400_20_RIGHT CCTTTGCTCCGTCCTAAGCTTG 2 
ZIKA_400_21_LEFT AGAGACTGACGAAGACCATGCA 1 
ZIKA_400_21_RIGHT CTCCAAAAGCCGCTCCTCTTTT 1 
ZIKA_400_22_LEFT TGGACCAGACACGGAGAGAAAA 2 
ZIKA_400_22_RIGHT ATTCTGGCTGGCTCAATTTCCG 2 
ZIKA_400_23_LEFT CGTCTTGATGAGGAACAAGGGC 1 
ZIKA_400_23_RIGHT AAGTGGTCACTGCATGTTGGAC 1 
ZIKA_400_24_LEFT TAATGGGAAGGAGAGAGGAGGG 2 
ZIKA_400_24_RIGHT TCTCCACTTGGGGGTCAATTGT 2 
ZIKA_400_25_LEFT CCCTGACCCTAATAGTGGCCAT 1 
ZIKA_400_25_RIGHT CCTTCCATTTCTCTCCCAGGGT 1 
ZIKA_400_26_LEFT ACTGGAACTCCTCTACAGCCAC 2 
ZIKA_400_26_RIGHT ACCAGGGCCTCCTTTTGTGTAT 2 
ZIKA_400_27_LEFT AGTGCAAAGCTGAGATGGTTGG 1 
ZIKA_400_27_RIGHT ATGTGTAGAGTTGCGGGAGAGT 1 
ZIKA_400_28_LEFT GGTGGGGGATTGGCTTGAAAAA 2 
ZIKA_400_28_RIGHT GGGCCTCATAGCTTCCATGGTA 2 
ZIKA_400_29_LEFT AGGATGTGAATCTCGGCTCTGG 1 
ZIKA_400_29_RIGHT ATGCTGCATTGCTACGAACCTT 1 
ZIKA_400_30_LEFT AAAAGTGGACACTAGGGTGCCA 2 
ZIKA_400_30_RIGHT TAATCCCAGCCCTTCAACACCA 2 
ZIKA_400_31_LEFT ACAAGGGGAATTTGGAAAGGCC 1 
ZIKA_400_31_RIGHT CGTAAGTGACAACTTGTCCGCT 1 
ZIKA_400_32_LEFT AAATGGAAAAAGGGCACAGGGC 2 
ZIKA_400_32_RIGHT TGTCCCATCCAGTTGAGGGTTT 2 
ZIKA_400_33_LEFT CAAACGAATGGCAGTCAGTGGA 1 
ZIKA_400_33_RIGHT ATCCACACTCTGTTCCACACCA 1 
ZIKA_400_34_LEFT ATTTCCACAGAAGGGACCTCCG 2 
ZIKA_400_34_RIGHT TGACTAGCAGGCCTGACAACAT 2 
ZIKA_400_35_LEFT ACCACCTGGGCTGAGAACATTA 1 
ZIKA_400_35_RIGHT ACCACTAGTCCCTCTTCTGGAG 1 
 
Supplementary Table 2 |​ Chikungunya virus “ChikAsiaECSA” 400 nt scheme. 
Name Sequence Pool 
CHIK_400_1_LEFT_3 CTTTTTGAAGGCCCTGCAACGT 1 
CHIK_400_1_RIGHT_3 ACGGCCATCACCTCTTGTAAGT 1 
CHIK_400_2_LEFT_0 TGTCGGACAGGAAGTACCACTG 2 
CHIK_400_2_RIGHT_0 CTCATCCGCCCAATTTGTCGAG 2 
CHIK_400_3_LEFT_0 GTACTGGGTAGGGTTCGACACA 1 
CHIK_400_3_RIGHT_0 CACACGAAACCACTGTGTCACA 1 
CHIK_400_4_LEFT_4 TCGGTGTTCCATCTAAAGGGCA 2 
CHIK_400_4_RIGHT_4 CTTCATGGTGTTCGTGTTCCGT 2 
CHIK_400_5_LEFT_0 GGTGGGGCTGAACCAGAGAATA 1 
CHIK_400_5_RIGHT_0 TACAAAGCTGTCGAATTCGGCC 1 
CHIK_400_6_LEFT_4 AAGCAGAAAACACACACGGTCT 2 
CHIK_400_6_RIGHT_4 GCGCCTCTCGGAGTCTCTATTA 2 
CHIK_400_7_LEFT_0 TACAGGCAGCACAGGAAGATGT 1 
CHIK_400_7_RIGHT_0 TGGAAGTCTTCGGGCGAAATTG 1 
CHIK_400_8_LEFT_1 GGAGCAAGTGAAGACGTGTACG 2 
CHIK_400_8_RIGHT_1 TATATGGACAAGCGGGGCGAAT 2 
CHIK_400_9_LEFT_0 TGCAAGAAGGAAGAAGCTGCAG 1 
CHIK_400_9_RIGHT_0 AAGGCGATCAAGGCAAGTAACG 1 
CHIK_400_10_LEFT_0 ATCTGCACGTACGGTTGATTCG 2 
CHIK_400_10_RIGHT_0 GGTTTTGTTGAGCCCGTAGTGT 2 
CHIK_400_11_LEFT_0 GGCAAAATGCGCACTACGAATG 1 
CHIK_400_11_RIGHT_0 CCTTCCGTACGCGTTAGGAGTA 1 
CHIK_400_12_LEFT_1 AGGAGTTTACGCAGTTAGGCAAA 2 
CHIK_400_12_RIGHT_1 TTCATTCAGGGCTACTTCGGGT 2 
CHIK_400_13_LEFT_0 TGGTCCCTATCCTCGAAACAGC 1 
CHIK_400_13_RIGHT_0 TCCTGGTAGTCACGCAGATCTG 1 
CHIK_400_14_LEFT_0 TGAGGCAGCGTCCATTCTAGAA 2 
CHIK_400_14_RIGHT_0 ATACCTACCAAGTGTTGCCGGT 2 
CHIK_400_15_LEFT_4 ACCTTGCACTGCCTACTAAGAGA 1 
CHIK_400_15_RIGHT_4 ACATGGTGGTTTCAATGCTCTGG 1 
CHIK_400_16_LEFT_0 TCAGAGCATACGGTTACGCAGA 2 
CHIK_400_16_RIGHT_0 TTTGCGGTTCCTACTGGTGTTG 2 
CHIK_400_17_LEFT_0 GACGGTGTTTGCAAGGCAGTAT 1 
CHIK_400_17_RIGHT_0 TCCATGGCTGTAAAGAGGTGGT 1 
CHIK_400_18_LEFT_0 ACCTCTCCTCTCCACAGGTGTA 2 
CHIK_400_18_RIGHT_0 GCCTCTATTTGCTTTGGCCACA 2 
CHIK_400_19_LEFT_0 AAGGGACACGTTTTCACCAGAC 1 
CHIK_400_19_RIGHT_0 GGAGCATTTGACTTTTTGCACTCC 1 
CHIK_400_20_LEFT_0 CGACTTCGCATGAACCATGTCA 2 
CHIK_400_20_RIGHT_0 GTATGTATCGCCCCGTCGTCTA 2 
CHIK_400_21_LEFT_0 AGTTTGATCTAAGCGCCGATGG 1 
CHIK_400_21_RIGHT_0 AAATGTGATGGGGAACGTCTCG 1 
CHIK_400_22_LEFT_0 CGCGTGACACAGCTATTTCCTT 2 
CHIK_400_22_RIGHT_0 TGGCGTACCGACTTCTGTTGTA 2 
CHIK_400_23_LEFT_0 ACACGGACGACGAGTTATGACT 1 
CHIK_400_23_RIGHT_0 GACAATCGGACGTTGATCGGAG 1 
CHIK_400_24_LEFT_0 TAATGGCAGAGACCCCGAAAGT 2 
CHIK_400_24_RIGHT_0 TGTGTTCTGGAATGGGGAAGGT 2 
CHIK_400_25_LEFT_0 CGAGCGACATTCAATCCGTCAA 1 
CHIK_400_25_RIGHT_0 CGGCAGCAGATTATGGGTTCTT 1 
CHIK_400_26_LEFT_3 GAAGAATTTGCTGCCAGCCCTA 2 
CHIK_400_26_RIGHT_3 GTGCGGCTATAATGGCATCGAA 2 
CHIK_400_27_LEFT_0 TTAGGAGATTGAACGCCGTCCT 1 
CHIK_400_27_RIGHT_0 GTCAGACGATCTTCCAACACCC 1 
CHIK_400_28_LEFT_2 GACAGGTACGCGCTTCAAGTTC 2 
CHIK_400_28_RIGHT_2 CGCTAACGGTTTGCCCAGTTTA 2 
CHIK_400_29_LEFT_0 AGCTCCCTACTTTTGTGGAGGG 1 
CHIK_400_29_RIGHT_0 GACCGCCGTACAAGGTTATGAC 1 
CHIK_400_30_LEFT_0 TAATGTCCATGGCCACCTTTGC 2 
CHIK_400_30_RIGHT_0 TATTCTTCCGATTCTTGCGCGG 2 
CHIK_400_31_LEFT_0 CAACTTGCCCAGCTGATCTCAG 1 
CHIK_400_31_RIGHT_0 ATCGATGGTCCCCTTTACGTGT 1 
CHIK_400_32_LEFT_0 TAAGGTAACAGGTTACGCGTGC 2 
CHIK_400_32_RIGHT_0 TACGGGCTCCTTCATTAGCTCC 2 
CHIK_400_33_LEFT_2 GACCGATCTTCGACAACAAGGG 1 
CHIK_400_33_RIGHT_2 GCGTCGGGGAGAACATGTTAAG 1 
CHIK_400_34_LEFT_0 GAGAAAACCTTGCGCATGCTTG 2 
CHIK_400_34_RIGHT_0 CTGCTGGCATGTGATTGTCCAT 2 
CHIK_400_35_LEFT_0 CCAGGTTTCCTTGCAAATCGGA 1 
CHIK_400_35_RIGHT_0 GTACGTGCTGCAAGGTAGTTCC 1 
CHIK_400_36_LEFT_1 CATGTACGCACCCATTTCACCA 2 
CHIK_400_36_RIGHT_1 GGTCCCCGAATTCAGCATTACG 2 
CHIK_400_37_LEFT_0 CTGCAAGGTCGATCAATGCCAT 1 
CHIK_400_37_RIGHT_0 TCATTGTTACCCCACGTGACCT 1 
CHIK_400_38_LEFT_0 AGTGGGTGACGCATAAGAAGGA 2 
CHIK_400_38_RIGHT_0 TGGTGTCAGTTCGTACGGTGTA 2 
CHIK_400_39_LEFT_0 ATACTCCTGTCGATGGTGGGTG 1 
CHIK_400_39_RIGHT_0 CGGGATCACTGTTACGTGTTCG 1 
CHIK_400_40_LEFT_0 TTTTTAGCCGTACTGAGCGTCG 2 
CHIK_400_40_RIGHT_0 ATTTTCGGTGTCGCAGAAGCAG 2 
CHIK_400_41_LEFT_0 GCGGTACAGCAGAGTGTAAGGA 1 
CHIK_400_41_RIGHT_0 GTCGCCTTTGTACACCACGATT 1 
CHIK_400_42_LEFT_0 CCATGCCGTCACAGTTAAGGAC 2 
CHIK_400_42_RIGHT_0 AGTTCATCGCTCTTACCGGGTT 2 
CHIK_400_43_LEFT_0 ATTGGCTAAAAGAACGAGGGGC 1 
CHIK_400_43_RIGHT_0 TTCCCGAATAGTGACGGCGTTA 1 
CHIK_400_44_LEFT_0 GCACCCATTCCTCAGACTTTGG 2 
CHIK_400_44_RIGHT_0 CCTGCTAAACGACACGCATAGC 2 
 
